Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.39 |
| ▸ | ITK | Q08881 | 12/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958074 | 1.00 | BTK (0.39) | BTKITKKLKB1F2JAK2 | |
| SCHEMBL30038499 | 0.83 | KLKB1 (0.46) | KLKB1F2MAP4K1 | |
| SCHEMBL17787108 | 0.83 | KLKB1 (0.46) | KLKB1F2MAP4K1 | |
| SCHEMBL27033831 | 0.80 | BTK (0.44) | BTKITKKLKB1F2MAP4K1 | |
| SCHEMBL29958524 | 0.80 | BTK (0.44) | BTKITKKLKB1F2MAP4K1 | |
| SCHEMBL27033870 | 0.79 | BTK (0.44) | BTKITKKLKB1F2MAP4K1 | |
| SCHEMBL29958243 | 0.79 | BTK (0.44) | BTKITKKLKB1F2MAP4K1 | |
| SCHEMBL12302707 | 0.77 | MTNR1A (0.37) | — | |
| SCHEMBL27033549 | 0.74 | KDR (0.50) | KLKB1JAK2JAK1JAK3CDK8 | |
| SCHEMBL23169558 | 0.73 | STK17B (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | BTK 1780/4885ITK 1085/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.